Citi Pharma Limited has received authorization from the Competition Commission of Pakistan (CCP) for its proposed acquisition of 100% shareholding in Pakheim International Pharma (Private) Limited. The development marks an important step forward in the company’s planned expansion through the acquisition.
According to a material information notice dated October 16, 2026, submitted to the Pakistan Stock Exchange (PSX), the CCP issued its order on October 9, 2026, in Case No. 1614/Merger-CCP/2026. The authorization allows the proposed transaction to proceed, following the commission’s review of the deal.
CCP Finds No Competition Concerns
Citi Pharma stated that the authorization was granted after the CCP reviewed the proposed transaction and determined that it did not raise competition concerns. The approval represents a key regulatory milestone for the planned acquisition.
The transaction is being carried out under Section 31(1)(d)(i) of the Competition Act, 2010. The company disclosed the development in accordance with Section 96 of the Securities Act, 2015, and the applicable provisions of the PSX Rule Book.
Acquisition Subject to Further Formalities
The proposed acquisition is based on a Share Purchase Agreement dated May 6, 2026. Citi Pharma noted that the transaction will proceed in accordance with the agreement’s terms and remains subject to the completion of applicable legal, regulatory and other formalities.
The company also stated that it will make further disclosures as required after the relevant milestones of the transaction have been completed.
Potential Significance for Citi Pharma
The proposed acquisition would give Citi Pharma full ownership of Pakheim International Pharma, potentially supporting its business expansion and strategic objectives. However, the company has not indicated in the disclosed notice when the transaction is expected to be completed or provided further details regarding its anticipated financial impact.
Investors and market participants will likely watch for subsequent announcements concerning the completion of the acquisition and any additional information disclosed by the company.
Conclusion
The Competition Commission of Pakistan’s authorization represents a significant regulatory step for Citi Pharma Limited’s proposed acquisition of Pakheim International Pharma. With the competition review completed without concerns being identified, the transaction can move forward subject to the remaining legal and regulatory requirements.
Further updates from Citi Pharma will clarify the completion timeline and the potential implications of the acquisition for the company’s future operations.
